Lucentis 10 mg/ml Solution for Injection in Pre-Filled Syringe

Manufacturer
NOVARTIS PHARMA STEIN A.G.
 
Contents
Ranibizumab
 
Indication
Neovascular (wet) age-related macular degeneration, Choroidal neovascularisation secondary to pathologic myopia, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion.
 
Instruction
Administer via Intravitreal to the affected eye.
 
Drug interaction
May enhance the adverse/toxic effect of belimumab. Serious intraocular inflammation may occur when used adjunctively w/ verteporfin photodynamic therapy (PDT).